INTSMEDIUM SIGNALFINANCIAL10-K

INTS executed a 1-for-25 reverse stock split while showing meaningful improvement in operating losses and cash burn rates.

The reverse stock split typically signals management's attempt to boost share price and potentially maintain exchange listing compliance, though it doesn't change the underlying business fundamentals. The improved financial metrics suggest better cost management and reduced cash consumption, which extends the company's operational runway.

Comparing 2026-03-27 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

INTS demonstrated meaningful financial improvement across key metrics, with operating losses narrowing by 27.8% to -$12.0M and cash burn improving substantially as operating cash flow moved from -$15.2M to -$9.2M. The improvement was driven primarily by a 35.4% reduction in R&D expenses to $6.8M, while liabilities increased modestly. Overall, the financial picture signals improved cost discipline and extended cash runway for this biotechnology company.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+39.3%
-$15.2M-$9.2M

Operating cash flow surged 39.3% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-35.4%
$10.5M$6.8M

R&D spending cut 35.4% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+28.7%
-$16.3M-$11.6M

Net income grew 28.7% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+27.8%
-$16.6M-$12.0M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Liabilities
Balance Sheet
+22.3%
$1.8M$2.1M

Current liabilities rose 22.3% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
+19.3%
$1.9M$2.2M

Liabilities increased 19.3% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-13
ADDED
As o f March 26, 2026, the registrant had 2,540,518 shares o f common stock, $0.0001 par value, outstanding.
On February 19, 2026, we effected a 1-for-25 reverse stock split of our common stock (the Reverse Stock Split ).
All historical share and per share amounts reflected throughout this Annual Report on Form 10-K have been adjusted to reflect the Reverse Stock Split.
The challenge with IT treatment approaches is that a tumor s stromal, high-fat, dense, poorly vascularized, and pressurized microenvironment is incompatible with and does not absorb water-based products.
We believe that this drug delivery challenge limits the effectiveness of prior and current IT treatments, which have involved injecting aqueous drugs into a tumor without sufficient consideration of the tumor environment.
+7 more — sign up free →
REMOVED
As o f March 12, 2025, the registrant had 15,180,945 shares o f common stock, $0.0001 par value, outstanding.
The challenge with IT treatment approaches is that a tumor s lipophilic, high fat, dense and pressurized microenvironment is incompatible with and does not absorb water-based products.
We believe that this drug delivery challenge limits the effectiveness of prior and current IT treatments, which involve injecting aqueous drugs into a tumor without sufficient consideration of the tumor environment (regardless of the drug s mechanism or approach, i.e.
We believe we have created a product candidate with the necessary chemistry to overcome this local delivery challenge.
We also sought to determine whether a local or whole-body anti-cancer immune response could be induced.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →